Email this article 
First results of 13-valent pneumococcal conjugate vaccine treatment in patients with chronic bronchopulmonary diseases: evaluation safety and tolerability
- Authors: Protasov AD1, Zhestkov AV1, Kostinov MP2
-
Affiliations:
- Samara State Medical University
- Federal State Institution of Vaccines and Sera behalf I.I. Mechnikov of Russian Academy of Medical Sciences
- Issue: Vol 10, No 4 (2013)
- Pages: 18-23
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/496
- DOI: https://doi.org/10.36691/RJA496
- ID: 496
Cite item
Open Access
Access granted
Abstract
The data on the safety and tolerability of vaccination with the 13valent conjugated vaccine against pneumococcal infection of patients with chronic bronchopulmonary diseases is cited. Background. To evaluate the safety and tolerability of 13valent pneumococcal conjugate vaccine in patients with chronic bronchopulmonary disorders (COPD and asthma). Methods. The study involved 67 patients with chronic bronchopulmonary diseases, 33 of them had COPD (group I), and 34 had asthma (group II). Patients received 1 dose of vaccine, «Prevenar13» intramuscularly in the left shoulder. Within 7 days after vaccination all subjects filled out specially designed questionnaire, reflecting the local and general adverse events. Results. Vaccination with 13valent pneumococcal conjugate vaccine of patients with COPD or asthma was well tolerated, no serious adverse events within 7 days of postvaccination period were observed.
Full Text
About the authors
A D Protasov
Samara State Medical University
Email: crosss82@mail.ru
A V Zhestkov
Samara State Medical University
M P Kostinov
Federal State Institution of Vaccines and Sera behalf I.I. Mechnikov of Russian Academy of Medical Sciences
References
- Roberto Rodriguez-Roisin et al. Global initiative for chronic obstructive lung disease. National Institutes of Health, 2011, p. 80.
- Лукачев И.В. Специфический IgG-, IgE- ответ и течение бронхиальной астмы у детей в процессе вакцинации препаратами «Пневмо-23» и «Акт-Хиб». Автореферат диссертации канд. мед. наук. М., 2004, 24 с.
- Standard and Poor’s. Старение населения - 2010: Российская Федерация. http://pensionreform.ru/1042.
- Всероссийская перепись населения 2010 г. http://www.gks. ru/free_doc/new_site/perepis2010/croc/perepis_itogi1612. htm.
- Чучалин А.Г. Современные подходы к вакцинопрофилактике пневмококковой инфекции у взрослых и пациентов групп риска: резолюция Междисциплинарного совета экспертов. Пульмонология. 2012, № 6, с. 139-142.
- De Backer W., Verhaegen J., Flamaing J. Clinical profile of adult patients with invasive pneumococcal disease (IPD) during a 3 years surveillance in Belgium. ERS 2012: Late breaking abstract 7059. http://www.ers-education.org/ers Made/ abstract_print_12// main_frameset.htm.
- Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine Preventable Diseases. The Pink Book. 11th Edition. May 2009, 256 p.
- Whitney C.G. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65. Geriatrics. 2003, v. 58 (10), p. 20-25.
- Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report. Emerging Infections Program Network. Streptococcus pneumoniae, 2009. http://www. cdc.gov/abcs/reports-findings/survreports/spneu09.pdf.
- Centers for Disease Control and Prevention. MMWR. Recommended Adult Immunization Schedule 2009; 57:Q1-Q4. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5753a6. htm. Accessed May 26, 2011.
- Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 2009, v. 9, p. 213-220.
- Nancy M. Bennett, Cynthia G. Whitney, Matt Moore et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of
- the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Rep. 2012, v. 61, p. 816-819.
- World Health Organization. 23-valent pneumococcal polysaccharide vaccine: WHO position paper. Wkly Epidemiol Rec. 2008, 83, p. 373-384.
- Prevenar 13 Fachinformation, Stand Oktober 2011.
- Weinberger B., Herndler-Brandstetter D., Schwanninger A. et al. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 2008, v. 46, p. 1078-1084.
- Paradiso P.R. Pneumococcal conjugate vaccine for adults: a new paradigm. Vaccines. CID. 2012, v. 55, p. 259-264.
- M. FitzGerald et al. Global initiative for asthma. National Institutes of Health. 2011, 110 p.
Supplementary files
